Suppr超能文献

基于结构的底物选择性抑制的计算设计

Computational design of substrate selective inhibition.

机构信息

Molecular Modeling Laboratory, Institute for Drug Research, The Hebrew University of Jerusalem, Jerusalem, Israel.

Laboratory of Cell Biology, Osaka University of Pharmaceutical Sciences, Osaka, Japan.

出版信息

PLoS Comput Biol. 2020 Mar 20;16(3):e1007713. doi: 10.1371/journal.pcbi.1007713. eCollection 2020 Mar.

Abstract

Most enzymes act on more than a single substrate. There is frequently a need to block the production of a single pathogenic outcome of enzymatic activity on a substrate but to avoid blocking others of its catalytic actions. Full blocking might cause severe side effects because some products of that catalysis may be vital. Substrate selectivity is required but not possible to achieve by blocking the catalytic residues of an enzyme. That is the basis of the need for "Substrate Selective Inhibitors" (SSI), and there are several molecules characterized as SSI. However, none have yet been designed or discovered by computational methods. We demonstrate a computational approach to the discovery of Substrate Selective Inhibitors for one enzyme, Prolyl Oligopeptidase (POP) (E.C 3.4.21.26), a serine protease which cleaves small peptides between Pro and other amino acids. Among those are Thyrotropin Releasing Hormone (TRH) and Angiotensin-III (Ang-III), differing in both their binding (Km) and in turnover (kcat). We used our in-house "Iterative Stochastic Elimination" (ISE) algorithm and the structure-based "Pharmacophore" approach to construct two models for identifying SSI of POP. A dataset of ~1.8 million commercially available molecules was initially reduced to less than 12,000 which were screened by these models to a final set of 20 molecules which were sent for experimental validation (five random molecules were tested for comparison). Two molecules out of these 20, one with a high score in the ISE model, the other successful in the pharmacophore model, were confirmed by in vitro measurements. One is a competitive inhibitor of Ang-III (increases its Km), but non-competitive towards TRH (decreases its Vmax).

摘要

大多数酶作用于不止一种底物。通常需要阻止酶在底物上的单一活性产物的产生,但又要避免阻止其其他催化作用。完全阻断可能会引起严重的副作用,因为该催化的一些产物可能是至关重要的。需要底物选择性,但通过阻断酶的催化残基无法实现。这就是“底物选择性抑制剂”(SSI)的基础,有几个分子被特征化为 SSI。然而,还没有通过计算方法设计或发现它们。我们展示了一种用于发现一种酶(脯氨酰寡肽酶(POP)(E.C 3.4.21.26)的计算方法,POP 是一种丝氨酸蛋白酶,可在脯氨酸和其他氨基酸之间切割小肽。其中包括促甲状腺素释放激素(TRH)和血管紧张素-III(Ang-III),它们在结合(Km)和周转率(kcat)上都有所不同。我们使用内部的“迭代随机消除”(ISE)算法和基于结构的“药效团”方法来构建两种识别 POP 的 SSI 模型。最初,约 180 万种商业上可获得的分子的数据集减少到不到 12000 种,这些分子通过这些模型进行筛选,最终得到了 20 种分子,这些分子被送去进行实验验证(随机测试了五个分子进行比较)。这 20 种分子中有两种,一种在 ISE 模型中的得分较高,另一种在药效团模型中成功,通过体外测量得到了证实。一种是 Ang-III 的竞争性抑制剂(增加其 Km),但对 TRH 是非竞争性的(降低其 Vmax)。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ae7/7112232/e6069041ffcc/pcbi.1007713.g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验